Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats

CNS Neuroscience and Therapeutics

Volumn 19, Issue 8, 2013, Pages 603-610

  Song, Yun ^a   Chen, Xu ^a   Wang, Li Yan ^b   Gao, Wei ^c   Zhu, Mei Jia ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

amyloid; Alzheimer's disease; Neuroinflammation; Rho kinase inhibitor

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FASUDIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL NUCLEUS; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IN VIVO STUDY; LEARNING; MALE; MEMORY DISORDER; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; RAT; SPATIAL LEARNING; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

Β-AMYLOID; ALZHEIMER'S DISEASE; NEUROINFLAMMATION; RHO KINASE INHIBITOR;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMYLOID BETA-PEPTIDES; ANIMALS; HIPPOCAMPUS; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES;

EID: 84880701367     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12116     Document Type: Article

References (26)

1. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010;9:237-248.
2. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-398.
3. Walsh DM, Klyubin I, Shankar GM, et al. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 2005;33:1087-1090.
4. Heneka MT, O'Banion MK. Neuroinflammatory processes in Alzheimer's disease. J Neuroimmunol 2007;184:69-91.
5. Li B, Zhong L, Yang X, Andersson T, Huang M, Tang SJ. WNT5A signaling contributes to Aβ-induced neuroinflammation and neurotoxicity. PLoS ONE 2011;6:e22920.
6. Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans 2011;39:886-890.
7. Kubo T, Yamaguchi A, Iwata N, Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008;4:605-615.
8. Doe C, Bentley R, Behm DJ, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007;320:89-98.
9. LoGrasso PV, Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009;9:704-723.
10. Chan CC. Inflammation: beneficial or detrimental after spinal cord injury? Recent Pat CNS Drug Discov 2008;3:189-199.
11. Ding J, Li QY, Wang X, Sun CH, Lu CZ, Xiao BG. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglia inflammatory response in mice. J Neurochem 2010;114:1619-1629.
12. Huentelman MJ, Stephan DA, Talboom J, et al. Peripheral Delivery of a ROCK Inhibitor Improves Learning and Working Memory. Behav Neurosci 2009;123:218-223.
13. Sayama CM, Liu JK, Couldwell WT. Update on endovascular therapies for cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006;21:E12.
14. Koumura A, Hamanaka J, Kawasaki K, et al. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. J Pharmacol Exp Ther 2011;338:337-344.
15. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005;238:31-39.
16. Li J, Wang C, Zhang JH, Cai JM, Cao YP, Sun XJ. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative stress. Brain Res 2010;1328:152-161.
17. Lingor P, Tönges L, Pieper N, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008;131:250-263.
18. Song H, Gao D. Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats. Int J Mol Med 2011;28:193-198.
19. Couch BA, DeMarco GJ, Gourley SL, Koleske AJ. Increased dendrite branching in AbetaPP/PS1 mice and elongation of dendrite arbors by fasudil administration. J Alzheimers Dis 2010;20:1003-1008.
20. 42 by inhibiting Rho. Science 2003;302:1215-1217.
21. Xiao F, Lin LF, Cheng X, Gao Q, Luo HM. Nogo-66 receptor activation inhibits neurite outgrowth and increases β-amyloid protein secretion of cortical neurons. Mol Med Rep 2012;5:619-624.
22. Conrad SSchluesener HJ, Trautmann K, Joannin N, Meyermann R, Schwab JM. Prolonged lesional expression of RhoA and RhoB following spinal cord injury. J Comp Neurol 2005;487:166-175.
23. Zhang Z, Fauser U, Schluesener HJ. Dexamethasone suppresses infiltration of RhoA(+) cells into early lesions of rat traumatic brain injury. Acta Neuropathol 2001;15:335.
24. Sun X, Minohara M, Kikuehi H. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune. J Neuroimmunol 2006;180:126-134.
25. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008;233:21-31.
26. Ye SM, Johnson RW. Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor kappaB. J Neuroimmunol 2001;117:87-96.